Approval of Drugs With Unmet Trial End Points-In Reply
JAMA Intern Med
.
2023 Aug 1;183(8):889-890.
doi: 10.1001/jamainternmed.2023.2240.
Authors
James L Johnston
1
,
Joseph S Ross
2
,
Reshma Ramachandran
2
Affiliations
1
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
2
Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
PMID:
37307009
DOI:
10.1001/jamainternmed.2023.2240
No abstract available
MeSH terms
Antineoplastic Agents*
Drug Approval
Humans
United States
United States Food and Drug Administration
Substances
Antineoplastic Agents